What the MV Hondius Hantavirus Outbreak Reveals About the UK Response and Japan’s Favipiravir Support

Because passengers disembarked across multiple countries, public‑health authorities expected additional cases to appear among contacts or returning travellers during the virus’s incubation period. Even so, European officials continue to assess the risk to the general population as very low.

How the UK responded

The United Kingdom treated the outbreak as a high‑consequence infectious disease event. The response has involved coordination between the UK Health Security Agency (UKHSA), the Foreign, Commonwealth & Development Office, the NHS, and international partners including the World Health Organization.

Measures have included:

• Repatriation and monitoring of exposed travellers
• Self‑isolation and health surveillance for contacts
• Access to specialist High Consequence Infectious Disease (HCID) facilities if severe illness develops
• International information sharing with other affected countries

This approach mirrors the playbook used for rare but potentially severe pathogens: identify exposed individuals, isolate suspected cases, and ensure specialist treatment capacity while transmission chains are traced.

Why Japan sent favipiravir (Avigan)

During the response, Japan provided the UK with doses of the antiviral drug favipiravir, also known as Avigan. The shipment was part of a public‑health collaboration between Japan’s Ministry of Health and the UKHSA.

The drug was supplied to strengthen treatment preparedness, not because it is a proven cure. Officials described the delivery as a way to bolster available treatment options should patients require experimental therapy.

Favipiravir is an antiviral originally developed for influenza. It works by interfering with viral RNA replication and has been investigated against several emerging RNA viruses.

In the context of hantavirus infections, its use would generally be considered experimental or compassionate, rather than routine care.

What scientists know about favipiravir and Andes virus

Research suggests the drug may have antiviral activity against hantaviruses, but the evidence is largely preclinical.

A widely cited 2013 study found that favipiravir inhibited replication of Sin Nombre virus and Andes virus in laboratory experiments and reduced viral detection in infected animal models.

These findings suggest the drug could potentially suppress hantavirus replication if given early enough in infection. However, translating results from laboratory or animal studies into successful human treatments is not guaranteed.

What remains unknown

The key gap is human clinical evidence.

Despite promising laboratory results, there is still no internationally established clinical protocol recommending favipiravir as standard treatment for hantavirus disease, and experts say its effectiveness in human cases of Andes virus remains uncertain.

More broadly, hantavirus diseases currently lack approved antiviral drugs or widely available vaccines, meaning treatment is usually focused on supportive medical care such as respiratory and intensive‑care support.

Because outbreaks involving person‑to‑person transmission are rare, opportunities to run large clinical trials are limited, leaving many potential treatments—including favipiravir—with incomplete evidence.

Why the wider public risk remains low

Even though Andes virus infections can be severe, global health authorities emphasize that the overall public‑health threat remains limited.

Several factors explain this assessment:

Transmission is relatively inefficient. Andes virus spreads mainly through close, prolonged contact, unlike highly contagious respiratory viruses.

The exposure source is well defined. Most infections are linked to people who were aboard the same cruise ship or had close contact with them.

Public‑health containment measures are active. Authorities are tracing contacts, isolating suspected cases, and monitoring travellers from the ship.

The World Health Organization’s risk assessments similarly indicate that the global risk is low, even though the risk for individuals who were directly exposed on the ship is higher.

The bigger lesson from the outbreak

The MV Hondius incident shows how governments respond to rare infectious threats that carry high severity but limited spread.

The response combines:

• rapid international coordination
• targeted containment measures
• precautionary medical stockpiling
• and the potential use of experimental treatments

Japan’s shipment of favipiravir illustrates that last point clearly: when proven therapies are scarce, preparedness may include keeping promising experimental drugs available while evidence continues to evolve.

For now, the outbreak remains dangerous for those directly exposed—but current evidence suggests it does not exhibit the transmission patterns needed to drive a broader pandemic.